Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core Viewpoint - Investors in Novo Nordisk A/S have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its business operations and prospects [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that from May 7, 2025, to July 28, 2025, Novo Nordisk failed to disclose critical information about its GLP-1 compounding practices, which included ignoring the significance of the personalization exception and overestimating its ability to attract patients transitioning from compounded treatments [3]. - The complaint claims that the positive statements made by the company regarding its business and operations were materially misleading and lacked a reasonable basis during the relevant period [3]. Group 2: Participation Information - Investors who suffered losses in Novo Nordisk are encouraged to contact the Law Offices of Howard G. Smith before September 30, 2025, to participate in the ongoing class action lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the Law Offices of Howard G. Smith via email or phone [4][5].